Coffee and cancer risk: A meta-analysis of prospective observational studies

Abstract

Meta-analyses on coffee and cancer incidence mainly restricted to limited cancers. We carried out a more comprehensive meta-analysis of cohort studies to explore association between coffee and most cancer types. We conducted comprehensive search and summarized relative risk (RR) and 95% confidence intervals for the highest versus lowest coffee intake and cancer using STATA12. We conducted dose-analysis if result suggested significant association. The publication bias was evaluated with begg’s and egger’s test. Finally, 105 individual prospective studies were included. Inverse associations were observed on oral, pharyngeal, colon, liver, prostate, endometrial cancer and melanoma, with RR 0.69 (95% CI = 0.48–0.99, I2 = 73.4%, P = 0.044), 0.87 (95% CI = 0.78–0.96, I2 = 28.4%, P = 0.007), 0.46 (95% CI = 0.37–0.57, I2 = 0%, P = 0), 0.89 (95% CI = 0.84–0.93, I2 = 30.3%, P = 0.003), 0.73 (95% CI = 0.67–0.80, I2 = 0%, P = 0) and 0.89 (95% CI = 0.80–0.99, I2 = 0%, P = 0.031) respectively. However, the relative risk for lung cancer is 2.18 (95% CI = 1.26–3.75, I2 = 63.3%, P = 0.005). The summary relative risk for increment of 2 cups of coffee were RR = 0.73, 95% CI = 0.67–0.79 for liver cancer, RR = 0.97, 95% CI = 0.96–0.98 for prostate cancer and RR = 0.88, 95% CI = 0.85–0.92 for endometrial cancer. Accordingly, coffee intake was associated with reduced risk of oral, pharynx, liver, colon, prostate, endometrial cancer and melanoma and increased lung cancer risk.

Risk factors for endometrial cancer: An umbrella review of the literature

“…The cohort studies from the excluded meta‐analyses for coffee intake were all included in the newer meta‐analyses . The other excluded meta‐analyses also had fewer cohorts included, despite being published more recently . Upon further comparison between the two and further investigation of the original studies, the excluded meta‐analysis also reported some incorrect relative risks in the analysis.…”

Prevalence of human papillomavirus in oral rinse samples from healthy individuals in northern Thailand

“…We found HPV to be more common among coffee drinkers (11.54%, 10/102 samples) than non‐coffee drinkers (3.05%, 12/492 samples) ( P = 0.002). On the other hand, coffee consumption appears to have a protective benefit in oral cancer …”

Molecular Docking and Pharmacokinetic of Highly Specific Novel Pan-Mtor Inhibitors against Solid Tumors

“…The indole group of Trp-2239 interacted with the morpholine ring and stacked with the pyrido-pyrimidine group in a way similar to ATP and Torin2. Trp-2239 contact is responsible for higher specificity over PI3K isoforms [2,18,24,35,36] One morpholine ring is surrounded by hydrophobic and the other by hydrophilic residues [37]. The side chain of Met-2345part of the N-lobe opposite to adenine binding pocket and Ile-2356 part of hydrophobic adenine site were involved in hydrophobic interactions with pyrido-pyrimidine group.…”

“…Member of Phosphoinositide 3-kinase (PI3K) family, mechanistic/mammalian target of rapamycin (mTOR) is a serine/threonine kinase and ortholog of yeast TOR protein [1,2]. mTOR is a key regulatory enzyme of PI3K/AKT/mTOR pathway and central modulator of cell growth, metabolism and survival [3].…”

“…mTORC2 inhibition mainly effects FOXO signaling pathway and is proved to be less toxic [17]. Besides being highly potent against several tumors none of ATP-competitive inhibitors entered clinical phase 3 or available commercially [2,18]. AZD2014, rationally designed pan-mTOR inhibitor currently in phase 1 of clinical trials, display higher specificity over PIKK family and exhibit better therapeutic effects against solid tumors [19][20][21].…”